Nextcure Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
60.4%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$7.46next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| LNCB74 Phase 1 Dose Escalation Trial Update | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
SIM0505 Phase 1 Dose Optimization Enrollment QuarterlyTarget: Up to 120 patients globally
Cash Runway Duration QuarterlyTarget: First half of 2027
LNCB74 Phase 1 Dose Escalation Progress QuarterlyTarget: Establish safety and recommended Phase 2 dose
Watch Items
- SIM0505 Phase 1 Dose Optimization Data ReadoutTrigger: Efficacy and safety data in platinum-resistant ovarian cancer (PROC)Action: Evaluate clinical proof-of-concept to support progression to pivotal studies
- LNCB74 Phase 1 Dose Escalation Trial UpdateTrigger: Initial safety and efficacy data readout in H2 2026Action: Assess therapeutic window and determine next clinical development steps
- Cash Burn Rate and Capital ResourcesTrigger: Cash reserves falling below $30 millionAction: Explore strategic partnerships, licensing agreements, or equity financing to extend runway
Research as of 20 Jun 2026